NEW YORK, March 20, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ARAY, ACRX, AEMD, and CHFS which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Accuray Inc. (NASDAQ: ARAY), AcelRx
Shares in Sunnyvale, California headquartered Accuray Inc. saw a decline of 1.85%, ending Monday's trading session at $5.30. The stock recorded a trading volume of 465,938 shares. The Company's shares have gained 0.95% in the last month, 19.10% over the last three months, and 4.95% over the past year. The stock is trading 13.93% above its 200-day moving average. Moreover, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have a Relative Strength Index (RSI) of 45.31. Get the full research report on ARAY for free by clicking below at: www.wallstequities.com/registration/?symbol=ARAY
Redwood City, California headquartered AcelRx Pharmaceuticals Inc.'s stock declined 3.61%, closing the day at $2.00 with a total trading volume of 392,718 shares. The Company's shares have advanced 14.29% in the past month and 2.56% in the previous three months. The stock is trading 2.96% above its 50-day moving average. Additionally, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 54.63.
On March 05th, 2018, AcelRx Pharma announced that that Vincent J. Angotti, CEO, will be presenting at the 28th Annual Oppenheimer Healthcare Conference on March 21st, 2018, at 11:30 a.m. ET at The Westin New York Grand Central in New York. The presentation will be webcast live and can be accessed under the Investors page of the Company's website. Access the free research report on ACRX now by signing up at: www.wallstequities.com/registration/?symbol=ACRX
On Monday, shares in San Diego, California-based Aethlon Medical Inc. recorded a trading volume of 485,794 shares. The stock ended the day 11.05% lower at $1.61. The Company's shares have advanced 5.92% in the past month and 31.97% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 6.23% and 7.59%, respectively. Furthermore, shares of Aethlon Medical, which focuses on creating devices that address unmet medical needs in health and biodefense worldwide, have an RSI of 50.34. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AEMD at: www.wallstequities.com/registration/?symbol=AEMD
Eden Prairie, Minnesota-based CHF Solutions Inc.'s stock dropped 1.96%, finishing yesterday's session at $4.00. A total volume of 595,017 shares, which was above their three months average volume of 501,730 shares. The Company's shares have advanced 31.15% in the last month and 6.38% in the previous three months. The stock is trading above its 50-day moving average by 12.92%. Additionally, shares of CHF Solutions, which develops cardiac and coronary disease products primarily in the US, have an RSI of 62.92.
On March 13th, 2018, CHF Solutions announced that its Q4 2017 and year-end 2017 financial results will be released on March 20th, 2018. The Company will host a conference call and webcast at 9:00 a.m. ET that morning, during which Management will discuss the results and provide a general business overview. The live webcast may be accessed under the Investors page of the Company's website. Aspiring Member, please take a moment to register below for your free research report on CHFS at: www.wallstequities.com/registration/?symbol=CHFS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-equipment-stocks----accuray-acelrx-pharma-aethlon-medical-and-chf-solutions-300616495.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All